

Supplemental Table 1. Baseline characteristics of matched HCC patients who received radiofrequency ablation according to tumor depth

Variable	Deep HCC (n = 32)	Non-deep HCC (n = 249)	SMD	Deep HCC (n = 27)	Non-deep HCC (n = 52)	SMD
Age (years)	58.6 ± 11.2	61.3 ± 11.0	-0.247	58.7 ± 12.0	58.3 ± 10.2	0.019
Male sex	24 (75.0)	182 (73.1)	-0.043	19 (70.4)	40 (76.9)	0.168
Maximal tumor diameter (D) (mm)	17.4 ± 5.4	17.4 ± 5.1	-0.006	17.7 ± 5.2	17.0 ± 4.5	0.082
Tumor number			-0.209			0.105
1/2	31 (96.9)/1 (3.1)	222 (89.2)/27 (10.8)		26 (96.3)/1 (3.7)	51 (98.1)/1 (1.9)	
Perivascular location			0.213			0.095
Portal vein/Hepatic vein	6 (18.8)/4 (12.5)	26 (10.4)/6 (2.4)		5 (18.5)/4 (14.8)	7 (13.5)/0 (0)	
Child-Pugh class B	5 (15.6)	2 (0.8)	0.402	1 (3.7)	1 (1.9)	0.000
Laboratory findings						
PLT ($\times 10^3/\text{mm}^3$)	124 (90–159)	120 (85–171)	0.169	125 (90–169)	115 (73–176)	0.107
ALT (IU/L)	37 (28–50)	34 (23–51)	-0.148	36 (28–52)	39 (22–61)	-0.097
Albumin (g/dL)	4.0 (3.4–4.2)	4.0 (3.7–4.3)	0.264	4.1 (3.8–4.2)	4.1 (3.7–4.4)	-0.059
Total bilirubin (mg/dL)	1.0 (0.6–1.4)	0.8 (0.6–1.1)	0.346	0.9 (0.6–1.2)	0.8 (0.6–1.2)	-0.019
Creatinine (mg/dL)	0.9 (0.7–1.0)	1.09 (1.04–1.16)	0.165	0.8 (0.7–1.0)	0.9 (0.7–1.0)	-0.061
Prothrombin time (INR)	1.11 (1.03–1.27)	0.85 (0.7–1.0)	0.283	1.09 (1.02–1.24)	1.11 (1.04–1.25)	-0.088
AFP (ng/dL)	7.9 (3.3–34.0)	6.6 (3.4–29.1)	0.120	8.8 (3.3–34.0)	7.6 (3.3–18.9)	-0.191

HCC, hepatocellular carcinoma; SMD, standardized mean difference; D, diameter; PLT, platelet count; ALT, alanine aminotransferase; INR, international normalized ratio; AFP, α -fetoprotein.